<DOC>
	<DOCNO>NCT00099021</DOCNO>
	<brief_summary>This phase II trial study well pioglitazone hydrochloride work prevent head neck cancer patient oral leukoplakia . Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use pioglitazone hydrochloride may effective prevent head neck cancer .</brief_summary>
	<brief_title>Pioglitazone Hydrochloride Preventing Head Neck Cancer Patients With Oral Leukoplakia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine whether pioglitazone ( pioglitazone hydrochloride ) reverse leukoplakia patient hyperplastic dysplastic oral cavity oropharyngeal leukoplakia . SECONDARY OBJECTIVES : I . Determine safety tolerability drug patient . OUTLINE : This open-label study . Patients receive pioglitazone hydrochloride orally ( PO ) daily ( QD ) 12 week absence disease progression , unacceptable toxicity , development carcinoma . Patients follow 4 , 8 , 12 , 16 week .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Leukoplakia , Oral</mesh_term>
	<mesh_term>Leukoplakia</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Criteria : ECOG 02 Diagnosis oral cavity oropharyngeal leukoplakia meeting 1 follow criterion : Biopsyproven hyperplasia highrisk anatomic area ( e.g. , floor mouth , mobile tongue , oropharynx , erythroplakia lesion ) Mild , moderate , severe dysplasia site oral cavity oropharynx within lesion Measurable lesion clinically characterize leukoplakia , erythroplakia , erythroleukoplakia Able assess bidirectional measurement Life expectancy : More 3 month Hemoglobin &gt; = low limit normal male postmenopausal female OR Hemoglobin &gt; = 11 g/dL premenopausal females WBC &gt; 3,000/mm^3 Hepatic : Bilirubin &lt; 1.5 time upper limit normal ( ULN ) ; AST ALT &lt; 1.5 time ULN Renal : BUN &lt; 1.5 time ULN ; Creatinine &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No contraindication thiazolidinediones No allergy pioglitazone thiazolidinediones No serious oral infection No invasive carcinoma within past 60 month except nonmelanoma skin cancer carcinoma situ cervix No concurrent malignancy More 3 month since prior biologic immunologic therapy No concurrent insulin diabetes No prior radiotherapy oral cavity More 3 month since prior chemopreventative agent More 3 month since prior experimental therapy More 3 month since prior megadose vitamin alternative therapy No prior thiazolidinediones No prior participation study No concurrent pharmacologic treatment diabetes Concurrent chronic use nonsteroidal antiinflammatory drug allow Platelet count &gt; 125,000/mm^3 Index lesion must locate anatomic site accessible punch biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>